Albuterol inhalers recalled after failing stability specification for particle size distribution
Cipla Albuterol Sulfate Inhalation Aerosol, 90 mcg, lot 4IB0519, is recalled nationwide after out-of-specification particle size distribution results at the 12-month stability point. 20,352 packs are affected.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The rubric puts FDA Class III actions at 1 or 2, and this is a stability test result outside specification with no health consequence described in the notice.
Plain-English summary
Albuterol Sulfate Inhalation Aerosol, 90 mcg, 200 metered inhalations, net content 6.7 g, is being recalled. The product is manufactured by Cipla Ltd in Indore, Pithampur, India for Cipla USA, Inc. of Warren, New Jersey. The affected product is lot 4IB0519 with an expiry of 04/30/2026, and the recall covers 20,352 packs distributed nationwide.
The recall was issued because the product failed stability specifications: out-of-specification results were observed in the induction port during analysis of particle size distribution at the 12-month time point. The FDA classified the action as Class III.
Patients should check the lot number on their inhaler against the recall and should speak to their pharmacist or prescriber about a replacement before stopping use of a prescribed inhaler.
The recalled product
- Product
- ALBUTEROL SULFATE (ALBUTEROL SULFATE)
- Brand
- ALBUTEROL SULFATE
- Manufacturer
- Cipla USA, Inc.
- Category
- Drug — Respiratory
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: 4IB0519
- Exp. 04/30/2026
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ALBUTEROL SULFATE
- ModerateAlbuterol sulfate inhalation aerosol recalled for temperature storage deviation
FDA (Drugs) · 2024-01-03
- HighAlbuterol Sulfate Inhaler Recalled Due to Temperature Storage Deviation
FDA (Drugs) · 2024-01-03
- CriticalPrescription albuterol inhalers recalled nationwide due to defective valve seals
FDA (Drugs) · 2023-07-19
- HighAlbuterol Sulfate Inhalation Aerosol Recalled for Temperature Abuse During Distribution
FDA (Drugs) · 2022-06-15
- High
Same manufacturer · Cipla USA, Inc.
See all →- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-08
- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- HighCipla cinacalcet 90 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
- HighCipla cinacalcet 60 mg tablets exceed the nitrosamine daily intake limit
FDA (Drugs) · 2026-04-22
Same hazard · failed specification
See all →- ModerateSodium iodide capsule packs recalled after failing capsule specifications
FDA (Drugs) · 2026-04-01
- HighMeclizine hydrochloride 12.5 mg tablets recalled after failing tablet specifications
FDA (Drugs) · 2026-04-01
- HighIcosapent ethyl capsules recalled after active ingredient oxidized inside capsule
FDA (Drugs) · 2026-03-18
- ModerateAmphetamine extended-release capsules 10 mg recalled over failed degradation specifications
FDA (Drugs) · 2025-10-01
- ModerateAmphetamine extended-release capsules 20 mg recalled over impurity and degradation results
FDA (Drugs) · 2025-10-01